Boston Scientific Corporation $BSX Stock: ZWJ Investment Counsel Inc. Raises Position

ZWJ Investment Counsel Inc. lifted its position in Boston Scientific Corporation (NYSE:BSX) by 25.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 739,647 shares of the medical equipment provider’s stock after acquiring an additional 149,431 shares during the quarter. ZWJ Investment Counsel Inc.’s holdings in Boston Scientific were worth $32,286,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific during the 1st quarter valued at $28,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Boston Scientific in the first quarter valued at $32,000. Measured Wealth Private Client Group LLC lifted its holdings in shares of Boston Scientific by 244.9% in the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 387 shares in the last quarter. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the second quarter worth $25,000. Finally, Boreal Capital Management LLC boosted its position in shares of Boston Scientific by 155.3% in the first quarter. Boreal Capital Management LLC now owns 646 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 393 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig bought 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David C. Habiger bought 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of a number of research analyst reports. Needham & Company LLC lowered their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 price target (down from $75.00) on shares of Boston Scientific in a research report on Thursday, July 30th. Jefferies Financial Group reduced their price objective on Boston Scientific from $67.00 to $60.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. The Goldman Sachs Group reduced their price objective on Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Finally, Canaccord Genuity Group decreased their price objective on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.23.

Boston Scientific Price Performance

NYSE BSX opened at $43.03 on Thursday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $62.36 billion, a PE ratio of 17.42, a price-to-earnings-growth ratio of 1.04 and a beta of 0.58. Boston Scientific Corporation has a 12-month low of $41.38 and a 12-month high of $105.65. The company has a 50 day moving average price of $46.26 and a two-hundred day moving average price of $49.97.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 3.25 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.